Ivermectin
Based on 48 publication(s) in Google Scholar
Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin (MK-933) is a specific inhibitor of Impα/β1-mediated nuclear import and has potent antiviral activity towards both HIV-1 and dengue virus. It is a positive allosteric effector of P2X4 and the α7 neuronal nicotinic acetylcholine receptor (nAChRs). Ivermectin also inhibits bovine herpesvirus1 (BoHV-1) replication and inhibits BoHV-1 DNA polymerase nuclear import. Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.28%
- No. CAS: 70288-86-7
- Fòrmula: C48H74O14
- Peso molecular:875.09
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Natural Product Library
HY-L021
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Antiviral Compound Library
HY-L027
-
CNS-Penetrant Compound Library
HY-L028
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Macrocyclic Compound Library
HY-L041
-
Antibacterial Compound Library
HY-L049
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antibiotics Library
HY-L067
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Antiparasitic Compound library
HY-L082
-
Microbial Metabolite Library
HY-L084
-
Mitochondria-Targeted Compound Library
HY-L089
-
Targeted Diversity Library
HY-L099
-
Pediatric Drug Library
HY-L104
-
Anti-Cancer Natural Product Library
HY-L107
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Nuclear Receptor Compound Library
HY-L126
-
Off-patent Drug Library
HY-L141
-
Mitochondrial Protection Compound Library
HY-L144
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Multi-Target Compound Library
HY-L176
-
Mitophagy Compound Library
HY-L180
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Pesticide Compound Library
HY-L183
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Animal Drug Library
HY-L218
-
Natural Product Diversity Scaffold Library
HY-L245
-
Environmental Pollutant Compound Library
HY-L247
-
RNA Binding Bioactive Compound Library
HY-L248
-
Bacteria-Sourced Compound Library
HY-L254
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Ivermectin
More- Cell. 2025 Sep 18;188(19):5266-5277.e13. [Abstract]
- Cell Mol Immunol. 2022 Aug;19(8):898-912. [Abstract]
- Autophagy. 2022 Mar;18(3):559-575. [Abstract]
- Adv Sci (Weinh). 2022 Dec;9(34):e2203088. [Abstract]
- Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121. [Abstract]
- Sci Adv. 2025 Aug 15;11(33):eadx6587. [Abstract]
- Redox Biol. 2026 May:92:104102. [Abstract]
- Cancer Lett. 2023 Jul 1:565:216218. [Abstract]
- Biomater Res. 2025 Nov 6:29:0278. [Abstract]
- EMBO J. 2022 Apr 22:e110324. [Abstract]
- Apoptosis. 2026 Mar 11;31(3):98. [Abstract]
- Biomed Pharmacother. 2024 Jun 20:177:116991. [Abstract]
- Biomed Pharmacother. 2022 Nov:155:113706. [Abstract]
- Cell Death Discov. 2025 Apr 10;11(1):162. [Abstract]
- Clin Transl Med. 2023 Apr;13(4):e1227. [Abstract]
- Antioxidants (Basel). 2024 May 29;13(6):667. [Abstract]
- Commun Med (Lond). 2025 Jul 1;5(1):249. [Abstract]
- JCI Insight. 2025 Jun 24;10(15):e193640. [Abstract]
- Inflammation. 2023 Oct;46(5):1626-1638. [Abstract]
- PLoS Pathog. 2026 Jan 26;22(1):e1013903. [Abstract]
- Pharmaceuticals (Basel). 2024 Apr 29;17(5):569. [Abstract]
- Front Pharmacol. 2021 Aug 13;12:717529. [Abstract]
- Int Immunopharmacol. 2024 Oct 9;143(Pt 1):113360. [Abstract]
- Eur J Pharmacol. 2022 Feb 5:916:174729. [Abstract]
- Neuropharmacology. 2026 Feb 12:110881. [Abstract]
- Mol Oncol. 2025 Jan;19(1):99-113. [Abstract]
- Cancers (Basel). 2021 Aug 6;13(16):3978. [Abstract]
- Biol Proced Online. 2025 Jun 16;27(1):21. [Abstract]
- J Cell Mol Med. 2024 Jul;28(14):e18539. [Abstract]
- Virol Sin. 2025 Mar 25:S1995-820X(25)00031-8. [Abstract]
- ACS Pharmacol Transl Sci. 2024 Jul 17;7(8):2496-2506. [Abstract]
- Viruses. 2026 Feb 10;18(2):221. [Abstract]
- Acta Biochim Biophys Sin (Shanghai). 2024 Nov 22;57(6):995-1005. [Abstract]
- PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. [Abstract]
- Virology. 2023 Oct:587:109877. [Abstract]
- J Anim Physiol Anim Nutr (Berl). 2020 Jul;104(4):1024-1033. [Abstract]
- Cancer Chemother Pharmacol. 2024 Jan;93(1):41-54. [Abstract]
- Connect Tissue Res. 2026 May;67(3):243-257. [Abstract]
- Neurosci Lett. 2021 Apr 17:750:135773. [Abstract]
- Anticancer Res. 2025 Feb;45(2):451-455. [Abstract]
- Anticancer Res. 2025 Jan;45(1):97-103. [Abstract]
- bioRxiv. 2025 Oct 15:2025.10.14.682432. [Abstract]
- Patent. US20250235403A1.
- bioRxiv. 2025 May 23:2025.05.18.654764. [Abstract]
- bioRxiv. 2025 March 19.
- bioRxiv. 2025 January 14.
- Patent. US20240417738A1.
- Oxid Med Cell Longev. 2021 Dec 21:2021:1172273. [Abstract]
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
Flow Cytometry
-
WB
-
Cell Autophagy Assay
Ver todos los productos específicos de isoformas Antibiotic
MoreVer todos los productos específicos de isoformas Parasite
More
Actividad biológica
|
HIV-1 |
DNA Polymerase |
HSV-1 |
BoHV-1 |
SARS-CoV-2 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Hepatocyte | IC50 |
10.42 μM
Compound: 2a; Fig 11, Cpd 2, MK933
|
Antimalarial activity against Plasmodium cynomolgi infected in rhesus macaque hepatocytes assessed as inhibition of liver-stage schizonts by Giemsa staining based microscopic analysis
Antimalarial activity against Plasmodium cynomolgi infected in rhesus macaque hepatocytes assessed as inhibition of liver-stage schizonts by Giemsa staining based microscopic analysis
|
[PMID: 34242031] |
| Huh-7 | IC50 |
2.1 μM
Compound: 2a; Fig 11, Cpd 2, MK933
|
Antimalarial activity against liver stage Plasmodium berghei infected in human Huh-7 cells assessed as inhibition by bioluminescence assay
Antimalarial activity against liver stage Plasmodium berghei infected in human Huh-7 cells assessed as inhibition by bioluminescence assay
|
[PMID: 34242031] |
| LLC-PK1 | IC50 |
0.1 μM
Compound: Ivermectin
|
Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay
Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay
|
[PMID: 12699389] |
| LLC-PK1 | IC50 |
0.5 μM
Compound: Ivermectin
|
Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay
Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay
|
[PMID: 12699389] |
| Macrophage | IC50 |
72.4 μM
Compound: 1, IVM
|
Cytotoxicity against mouse peritoneal macrophages assessed as LDH release after 48 hrs
Cytotoxicity against mouse peritoneal macrophages assessed as LDH release after 48 hrs
|
[PMID: 19114308] |
| Macrophage | CC50 |
427.5 μM
Compound: IVM
|
Cytotoxicity against BALB/c mouse macrophage assessed as cell viability measured after 48 hrs by MTT assay
Cytotoxicity against BALB/c mouse macrophage assessed as cell viability measured after 48 hrs by MTT assay
|
[PMID: 37793327] |
| Vero | CC50 |
52.84 μg/mL
Compound: Ivermectin
|
Cytotoxicity against african green monkey Vero cells after 72 hrs by resazurin dye-based fluorimetric analysis
Cytotoxicity against african green monkey Vero cells after 72 hrs by resazurin dye-based fluorimetric analysis
|
[PMID: 22348826] |
| Vero | CC50 |
230 μM
Compound: Ivermectin
|
Cytotoxicity against African green monkey Vero C1008 cells assessed as cell death by three-fold serial dilution method
Cytotoxicity against African green monkey Vero C1008 cells assessed as cell death by three-fold serial dilution method
|
[PMID: 24863844] |
| Vero | CC50 |
53.15 μM
Compound: Ivermectin
|
Cytotoxicity against African green monkey Vero cells after 72 hrs by resazurin dye-based fluorescence assay
Cytotoxicity against African green monkey Vero cells after 72 hrs by resazurin dye-based fluorescence assay
|
[PMID: 25768703] |
| Vero | CC50 |
53.15 μM
Compound: Ivermectin
|
Cytotoxicity against African green monkey Vero cells after 72 hrs by resazurin dye-based fluorometric analysis
Cytotoxicity against African green monkey Vero cells after 72 hrs by resazurin dye-based fluorometric analysis
|
[PMID: 26383126] |
In the submicromolar range (EC50=250 nM) the action of Ivermectin (MK-933) is rapid and reversible, resulting in increased amplitude and slowed deactivation of P2X4 channel currents evoked by ATP[1].
Ivermectin (MK-933) markedly increases the potency of ATP and that of the normally low-potency agonist a,b-methylene-ATP in a use- and voltage-independent manner without changing the ion selectivity of P2X4 channels[1].
Ivermectin (MK-933) activates glutamate-gated chloride channels in the nerves and muscles of the parasite, leading to membrane hyperpolarization and muscle paralysis[2].
Ivermectin (MK-933) strongly inhibits the binding of Impα/β1 to NS5 (IC50=17 μM), but not of Impβ1 alone to NS5[3].
Ivermectin (MK-933) has potent antiviral activity towards both HIV-1 and dengue virus, both of which are strongly reliant on importin α/β nuclear import, with respect to the HIV-1 integrase and NS5 (non-structural protein 5) polymerase proteins respectively[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 70288-86-7
-
Appearance Solid
-
Peso molecular 875.09
-
Fòrmula C48H74O14
-
Color White to off-white
-
SMILES
CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@H](/C(C)=C/C[C@@H]3C[C@H]4C[C@@]5(O[C@]([H])(C(C)C)[C@@H](C)CC5)O3)[C@@H](C)/C=C/C=C6CO[C@@]7([H])[C@]\6(O)[C@H](C(O4)=O)C=C(C)[C@H]7O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O.CO[C@H]8C[C@H](O[C@H]9[C@H](C)O[C@@H](O[C@H](/C(C)=C/C[C@@H]%10C[C@H]%11C[C@@]%12(O[C@]([H])([C@@H](C)CC)[C@@H](C)CC%12)O%10)[C@@H](C)/C=C/C=C%13CO[C@@]%14([H])[C@]\%13(O)[C@H](C(O%11)=O)C=C(C)[C@H]%14O)C[C@@H]9OC)O[C@@H](C)[C@@H]8O
-
Synonyms
MK-933; CD-5024; K-237
-
Structure Classification
-
Initial Source
Streptomyces avermitilis
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (48)
-
Journal Impact Factor
-
Most Recent
-
Cell
2025 Sep 18;188(19):5266-5277.e13. PMID: 40570835 -
Cell Mol Immunol
ADAP restraint of STAT1 signaling regulates macrophage phagocytosis in immune thrombocytopenia. [Abstract]2022 Aug;19(8):898-912. PMID: 35637282
Ivermectin purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2022 Aug;19(8):898-912. [Abstract]
Ivermectin (1-3 mg/kg; i.p.). Platelet counts in WT (upper panel) and Adap−/− mice (lower panel) treated with Ivermectin or saline over a time course of 5 days.
Ivermectin purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2022 Aug;19(8):898-912. [Abstract]
Ivermectin (1-3 mg/kg; i.p.). FcγR expressions on resting and IFN-γ-treated splenic macrophages in WT and Adap−/− mice treated with ivermectin for 5 days from.
-
Autophagy
Piperine promotes autophagy flux by P2RX4 activation in SNCA/α-synuclein-induced Parkinson disease model. [Abstract]2022 Mar;18(3):559-575. PMID: 34092198
Ivermectin purchased from MedChemExpress. Usage Cited in: Autophagy. 2022 Mar;18(3):559-575. [Abstract]
Ivermectin (IVE; 10 μM; 24 h). Hs-SNCA, p-SNCA, LC3-II and SQSTM1/p62 levels were elevated by western blotting.
Ivermectin purchased from MedChemExpress. Usage Cited in: Autophagy. 2022 Mar;18(3):559-575. [Abstract]
Ivermectin (IVE; 10 μM; 24 h). Autophagy flux was evaluated by counting autophagosome (RFP-GFP double positive puncta) and autolysosomes (RFP-single positive puncta) in mRFP-GFP-LC3 primary neurons.
-
Adv Sci (Weinh)
SRSF5-Mediated Alternative Splicing of M Gene is Essential for Influenza A Virus Replication: A Host-Directed Target Against Influenza Virus. [Abstract]2022 Dec;9(34):e2203088. PMID: 36257906 -
Nucleic Acids Res
COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics. [Abstract]2021 Jan 8;49(D1):D1113-D1121. PMID: 33166390 -
Sci Adv
2025 Aug 15;11(33):eadx6587. PMID: 40815641
Ivermectin purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Aug 15;11(33):eadx6587. [Abstract]
Ivermectin (IVM; 12.5 mg/kg; ip). Tumor growth of B16 in C57BL/6 mice treated with IVM, α-PD-1, or both.
-
Redox Biol
SMURF2 attenuates NRF2-driven tumor progression by acting as a nuclear brake on NRF2 during cellular stress. [Abstract]2026 May:92:104102. PMID: 41926909 -
Cancer Lett
Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma. [Abstract]2023 Jul 1:565:216218. PMID: 37149018 -
Biomater Res
Purinergic Receptor Nanoimmunoamplifiers Potentiate Chemoimmunotherapy Efficacy in Hepatocellular Carcinoma. [Abstract]2025 Nov 6:29:0278. PMID: 41209313 -
EMBO J
TFAM loss induces nuclear actin assembly upon mDia2 malonylation to promote liver cancer metastasis. [Abstract]2022 Apr 22:e110324. PMID: 35451091 -
Apoptosis
2026 Mar 11;31(3):98. PMID: 41813919 -
Biomed Pharmacother
Novel selective inhibitors of macropinocytosis-dependent growth in pancreatic ductal carcinoma. [Abstract]2024 Jun 20:177:116991. PMID: 38906021 -
Biomed Pharmacother
2022 Nov:155:113706. PMID: 36116250 -
Cell Death Discov
Mutant p53 upregulates HDAC6 to resist ER stress and facilitates Ku70 deacetylation, which prevents its degradation and mitigates DNA damage in colon cancer cells. [Abstract]2025 Apr 10;11(1):162. PMID: 40210861 -
Clin Transl Med
2023 Apr;13(4):e1227. PMID: 37085966 -
Antioxidants (Basel)
Pitavastatin Calcium Confers Fungicidal Properties to Fluconazole by Inhibiting Ubiquinone Biosynthesis and Generating Reactive Oxygen Species. [Abstract]2024 May 29;13(6):667. PMID: 38929106 -
Commun Med (Lond)
AI-enabled drug prediction and gene network analysis reveal therapeutic use of vorinostat for Rett Syndrome in preclinical models. [Abstract]2025 Jul 1;5(1):249. PMID: 40595330 -
JCI Insight
2025 Jun 24;10(15):e193640. PMID: 40553562 -
Inflammation
Ivermectin Protects Against Experimental Autoimmune Encephalomyelitis in Mice by Modulating the Th17/Treg Balance Involved in the IL-2/STAT5 Pathway. [Abstract]2023 Oct;46(5):1626-1638. PMID: 37227550 -
PLoS Pathog
Anti-orthopoxvirus drugs inhibit lumpy skin disease virus replication by targeting viral DNA polymerase. [Abstract]2026 Jan 26;22(1):e1013903. PMID: 41587213 -
Pharmaceuticals (Basel)
Computational Modeling to Identify Drugs Targeting Metastatic Castration-Resistant Prostate Cancer Characterized by Heightened Glycolysis. [Abstract]2024 Apr 29;17(5):569. PMID: 38794139 -
Front Pharmacol
2021 Aug 13;12:717529. PMID: 34483925 -
Int Immunopharmacol
Inhibition of KPNA2 by ivermectin reduces E2F1 nuclear translocation to attenuate keratinocyte proliferation and ameliorate psoriasis-like lesions. [Abstract]2024 Oct 9;143(Pt 1):113360. PMID: 39388894 -
Eur J Pharmacol
2022 Feb 5:916:174729. PMID: 34973190 -
Neuropharmacology
Ivermectin reduces withdrawal-induced alcohol intake in rats: Association with CeA GABAergic enhancement and P2rx4 genetic liability. [Abstract]2026 Feb 12:110881. PMID: 41690511 -
Mol Oncol
Importin subunit beta-1 mediates ERK5 nuclear translocation, and its inhibition synergizes with ERK5 kinase inhibitors in reducing cancer cell proliferation. [Abstract]2025 Jan;19(1):99-113. PMID: 38965815 -
Cancers (Basel)
Drug Repurposing to Identify a Synergistic High-Order Drug Combination to Treat Sunitinib-Resistant Renal Cell Carcinoma. [Abstract]2021 Aug 6;13(16):3978. PMID: 34439134 -
Biol Proced Online
Establishment of a mouse lung cancer organoid model and its applications for therapeutic screening. [Abstract]2025 Jun 16;27(1):21. PMID: 40524168 -
J Cell Mol Med
Overcoming flumatinib resistance in chronic myeloid leukaemia: Insights into cellular mechanisms and ivermectin's therapeutic potential. [Abstract]2024 Jul;28(14):e18539. PMID: 39046364 -
Virol Sin
Development of a reporter HBoV1 strain for antiviral drug screening and life cycle studies. [Abstract]2025 Mar 25:S1995-820X(25)00031-8. PMID: 40147635 -
ACS Pharmacol Transl Sci
Ivermectin Synergizes with Modulated Electro-hyperthermia and Improves Its Anticancer Effects in a Triple-Negative Breast Cancer Mouse Model. [Abstract]2024 Jul 17;7(8):2496-2506. PMID: 39144564 -
Viruses
2026 Feb 10;18(2):221. PMID: 41754564 -
Acta Biochim Biophys Sin (Shanghai)
Ivermectin inhibits the growth of ESCC by activating the ATF4-mediated endoplasmic reticulum stress-autophagy pathway. [Abstract]2024 Nov 22;57(6):995-1005. PMID: 39574166 -
PLoS Negl Trop Dis
Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]2019 Aug 20;13(8):e0007681. PMID: 31430351 -
Virology
Evaluating anti-viral effect of Ivermectin on porcine epidemic diarrhea virus and analyzing the related genes and signaling pathway by RNA-seq in vitro. [Abstract]2023 Oct:587:109877. PMID: 37688922 -
J Anim Physiol Anim Nutr (Berl)
Effect of air temperature on growth performance, apparent digestibilities, rumen fermentation and serum metabolites in Altay and Hu lambs. [Abstract]2020 Jul;104(4):1024-1033. PMID: 32011791 -
Cancer Chemother Pharmacol
Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells. [Abstract]2024 Jan;93(1):41-54. PMID: 37741955 -
Connect Tissue Res
Collagen I alleviates UVB-induced oxidative DNA damage and inhibits YAP-p73 apoptotic pathway in human keratinocytes HaCaT. [Abstract]2026 May;67(3):243-257. PMID: 41700367 -
Neurosci Lett
P2X4 receptor in the dorsal horn contributes to BDNF/TrkB and AMPA receptor activation in the pathogenesis of remifentanil-induced postoperative hyperalgesia in rats. [Abstract]2021 Apr 17:750:135773. PMID: 33639220 -
Anticancer Res
Recombinant Methioninase (rMETase) Synergistically Sensitizes Ivermectin-resistant MCF-7 Breast Cancer Cells 9.9 Fold to Low-dose Ivermectin. [Abstract]2025 Feb;45(2):451-455. PMID: 39890170 -
Anticancer Res
Ivermectin Combined With Recombinant Methioninase (rMETase) Synergistically Eradicates MiaPaCa-2 Pancreatic Cancer Cells. [Abstract]2025 Jan;45(1):97-103. PMID: 39740811 -
bioRxiv
2025 Oct 15:2025.10.14.682432. PMID: 41279989 -
-
bioRxiv
2025 May 23:2025.05.18.654764. PMID: 40475632 -
-
-
-
Oxid Med Cell Longev
FOXO1 Is a Critical Switch Molecule for Autophagy and Apoptosis of Sow Endometrial Epithelial Cells Caused by Oxidative Stress. [Abstract]2021 Dec 21:2021:1172273. PMID: 34970413
Solvente y solubilidad
DMSO : 250 mg/mL (285.68 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.86 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 3.33 mg/mL (3.81 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (288 KB)
-
SDS (623 KB)
- English - EN (623 KB)
- Français - FR (623 KB)
- Deutsch - DE (623 KB)
- Norwegian - NO (623 KB)
- Español - ES (623 KB)
- Swedish - SV (623 KB)
- Italian - IT (623 KB)
- Portuguese - PT (623 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Khakh BS, et al. Allosteric control of gating and kinetics at P2X(4) receptor channels. J Neurosci. 1999 Sep 1;19(17):7289-99. [Content Brief]
[2]. Priel A, et al. Mechanism of ivermectin facilitation of human P2X4 receptor channels. J Gen Physiol. 2004 Mar;123(3):281-93. [Content Brief]
[3]. Wagstaff KM, et al. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J. 2012 May 1;443(3):851-6. [Content Brief]
[4]. Raza S, et al. Ivermectin Inhibits Bovine Herpesvirus 1 DNA Polymerase Nuclear Import and Interferes with Viral Replication. Microorganisms. 2020 Mar 13;8(3). pii: E409. [Content Brief]
[5]. Khan Sharun, et al. Ivermectin, a New Candidate Therapeutic Against SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrob. 2020 May 30;19(1):23. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.1427 mL | 5.7137 mL | 11.4274 mL | 28.5685 mL |
| 5 mM | 0.2285 mL | 1.1427 mL | 2.2855 mL | 5.7137 mL | |
| 10 mM | 0.1143 mL | 0.5714 mL | 1.1427 mL | 2.8568 mL | |
| 15 mM | 0.0762 mL | 0.3809 mL | 0.7618 mL | 1.9046 mL | |
| 20 mM | 0.0571 mL | 0.2857 mL | 0.5714 mL | 1.4284 mL | |
| 25 mM | 0.0457 mL | 0.2285 mL | 0.4571 mL | 1.1427 mL | |
| 30 mM | 0.0381 mL | 0.1905 mL | 0.3809 mL | 0.9523 mL | |
| 40 mM | 0.0286 mL | 0.1428 mL | 0.2857 mL | 0.7142 mL | |
| 50 mM | 0.0229 mL | 0.1143 mL | 0.2285 mL | 0.5714 mL | |
| 60 mM | 0.0190 mL | 0.0952 mL | 0.1905 mL | 0.4761 mL | |
| 80 mM | 0.0143 mL | 0.0714 mL | 0.1428 mL | 0.3571 mL | |
| 100 mM | 0.0114 mL | 0.0571 mL | 0.1143 mL | 0.2857 mL |
Powered by Bioz